The gonadotrophin-releasing hormone antagonist ganirelix—History and introductory data

References

• Baba Y, Matsuo H, Schally V. Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analysis. Biochemical and Biophysical Research Communications 1971; 44: 459–463
   PubMed Web of Science ®Google Scholar
• de Jong D, Van Hooren EG, Macklon NS, Mannaerts BMJL, Fauser BCJM. Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using a GnRH antagonist (Antagon/Orgalutran) to prevent a premature LH surge: a case report. Journal of Assisted Reproduction and Genetics 2001; 18: 30–33
   Google Scholar
• European and Middle East Orgalutran® Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 2001; 16: 644–651
   Google Scholar
• European Orgalutran® Study Group, Borm G, Mannacrts B. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction 2000; 15: 1490–1498
   Google Scholar
• Fauser, BCJM, de Jong, D, Olivennes, F, Wramsby, H, Tay, C, Itskovitz-Eldor, J, vanHooren, HG. Endocrine profiles following triggering of final oocyte maturation with gonadotropin-releasing homrone (GnRH) agonist after co-treatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for IVF. Journal of Clinical Endocrinology and Metabolism, in press, 2002; 87
   Google Scholar
• Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the GnRH antagonist ganirelix (Org 37642) to prevent premature LH surges in women undergoing controlled ovarian hyperstimulation with recombinant FSH (Puregon®). Human Reproduction 1998; 13: 3023–3031
   Google Scholar
• Itskovitz-Eldor J, Kol S, Mannaerts B, Coelingh Bennink HC. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotropin-releasing hormone antagonist ganirelix (Org 37642). Human Reproduction 1998; 13: 294–295
   PubMedGoogle Scholar
• Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Human Reproduction 2000; 15: 1965–1968
   PubMed Web of Science ®Google Scholar
• Kol, S, Lightman, A, Hillensjö, T, et al. High doses of GnRH antagonist in IVF do not adversely affect the outcome of subsequent freeze-thaw cycles. Human Reproduction 1999; 14: 2242–2244
   PubMed Web of Science ®Google Scholar
• Lemay, A, Maheux, R, Faure, N, et al. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LHRH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertility and Sterility 1984; 41: 863–871
   PubMed Web of Science ®Google Scholar
• Mannaerts B, Gordon K. Embryo implantation and GnRH antagonists. GnRH antagonists do not activate the GnRH receptor. Human Reproduction 2000; 15: 1882–1883
   PubMed Web of Science ®Google Scholar
• North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 2001; 75: 35–45
   Google Scholar
• Oberyé JJL, Mannaerts BMJL, Kleijn HJ, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristicis of ganirelix (Orgalutran). Part I. Absolute bioavailability of 0.25 mg ganirelix after single subcutaneous injection in healthy female volunteers. Fertility and Sterility 1999a; 72: 1001–1005
   PubMed Web of Science ®Google Scholar
• Oberyé JJL, Mannaerts BMJL, Huisman JAM, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristicis of ganirelix (Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertility and Sterility 1999b; 72: 1006–1012
   PubMed Web of Science ®Google Scholar
• Olivennes F, Mannaerts B, Struijs M, Bonduelle M, Devroey P. Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Human Reproduction 2001; 16: 1588–1591
   PubMed Web of Science ®Google Scholar
• Porter, RN, Smith, W, Craft, IL, et al. Induction of ovulation for in vitro fertilisation using buserelin and gonadotropins. Lancet 1984; 2: 1284–1285
   PubMed Web of Science ®Google Scholar
• Reismann T, Schally AV, Bouchard P, Riethmuller H, Engel J. The LHRH-antagonist Cetrorelix: a review. Human Reproduction Update 2000; 6: 322–331
   Google Scholar
• Schally AV, Halmos G, Rekasi Z, Arencibia-Jimenez JM. The actions of luteinizing hormone-releasing hormone agonists, antagonists, and cytotoxic analogues on the luteinizing hormone-releasing hormone receptors on the pituitary and tumors. Infertility and Reproductive Medicine Clinics of North America 2001; 12: 17–44
   Google Scholar